Introduction The treatment of diabetes mellitus is complicated and involved. Dietary restrictions, regular doses of medication, and constant monitoring of blood sugar levels can be very time-consuming. The complications that can arise with the condition can be dangerous, or even life-threatening. However, it is entirely possible to live a long and healthy life with diabetes, especially if one is careful. Remaining physically fit and regularly monitoring one’s blood sugar are essential, but perhaps the most important thing that a diabetic can do to remain healthy is know which foods are the safest to eat and which ones should be avoided…. Read more.
The actual cause of bladder cancer is not known. However, there are a number of factors that increases the risks. Generally, these factors may include physiological traits, medical conditions and other external causes. Physiological Risk Factors Physiological factors that increase a person’s risk for bladder cancer include: Age. Risk factors increase as a person ages. It is rarely diagnosed in people under 40. Gender. Men are up to four times likely to develop bladder cancer than women. Race. White people are more likely to develop bladder cancer in the U.S. than Hispanics or African-Americans. Races with the lowest diagnoses of… Read more.
Benefits Outweigh Risks Associated With Actos® (Pioglitazone) In Patients With Hard To Control Diabetes
The United States Food and Drug Administrative (FDA) has issued a mandate that the label for pioglitazone (Actos® , Takeda) be updated to show the increased risk of cancer found to be associated with use of the drug. On June 15, 2011 labeling for the drug was updated due to a clinical review that confirmed patients who are treated with pioglitazone for treatment periods of 12 months or longer may have an increased risk of bladder cancer (1). The label specifically indicates that pioglitazone is not recommended for patients who already battle bladder cancer. In addition, the label states that… Read more.
Despite research showing that the drug may relate to an increased risk of bladder cancer in patients, the European Medicines Agency (EMA) has stated that the diabetes drug Actos® may be kept available on the market with warnings (1). A statement published on the EMA website states that the benefits of Actos® may outweigh the risks to some patients struggling with type 2 diabetes. Supporting the decision made by the United States Food and Drug Administration (FDA), the European agency agrees that that there is a small increased risk of bladder cancer in patients taking Actos®. Sales of Actos® currently… Read more.